[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"rosai-dorfman-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:rosai-dorfman-disease":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,48,85,108],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100509575","histiocytic-disorder-follow-up-study-100509575",false,"NCT05915208","Histiocytic Disorder Follow-up Study","Inclusion Criteria:\n\n* diagnosis of histiocytic disorder at any age\n\n  1. Langerhans cell histiocytosis,\n  2. Erdheim-Chester disease,\n  3. Rosai-Dorfman disease,\n  4. Xanthogranuloma,\n  5. Mixed histiocytosis\n  6. Malignant histiocytosis (Histiocytic sarcoma, langerhans cell sarcoma, interdigitating cell sarcoma)\n  7. Hemophagocytic lymphohistiocytosis\n\nExclusion Criteria:\n\n* None","ALL","0 Years","89 Years",{"count":19,"type":20},6000,"ESTIMATED","OBSERVATIONAL","The purpose of the study is to describe the burden of chronic health conditions, psychological dysfunction, chronic pain, healthcare utilization, worse health-related quality of life, overall mortality, and cause-specific mortality among individuals with histiocytic disorders",[24,25,26,27,28,29],"Histiocytosis","Langerhans Cell Histiocytosis","Erdheim-Chester Disease","Rosai Dorfman Disease","Xanthogranuloma","Malignant Histiocytoses",[31,32,33,34],"survivorship","long-term","targeted therapy","second cancer","RECRUITING","2026-06-10",{"date":38,"type":39},"2026-06-12","ACTUAL",{"date":41,"type":39},"2022-09-01",{"date":43,"type":20},"2028-12",{"name":45,"class":46},"University of Alabama at Birmingham","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":15,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":67,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":47},"100446430","early-phase-1-in-human-cxcr4-imaging-of-hematologic-and-solid-tumors-using-68ga-pentixafor-pet-100446430","NCT05093335","In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET","In-human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET","Inclusion Criteria:\n\nTwenty patients with histologically proven treatment-naïve, therapy-refractory or relapsed blood cancers meeting the below criteria will be included:\n\n* Indolent B- or T-cell Non-Hodgkin lymphoma (including cutaneous lymphomas) or Non-Hodgkin lymphoma with variable FDG uptake and clinical course, such as mantle cell lymphoma; and measurable disease according to Lugano criteria\n\nor\n\n* Histiocytic neoplasms (Langerhans cell histiocytosis (LCH), Erdheim-Chester disease (ECD) and\u002For Rosai-Dorfman disease (RDD)\n* MGUS\u002FSMM or MM according to IMWG definitions\n* Solid tumors, such as lung cancers, meningioma, adrenocortical neoplasms including cortisol-producing adenomas or high suspicion for tumor, such as in patients with Cushing's disease.\n* Age ≥18\n* Negative serum pregnancy test for female volunteers of childbearing age and potential (as defined by MSKCC Standards \\& Guidelines) from assays obtained \\\u003C2 weeks prior to study enrollment\u002Fintervention; or negative urine pregnancy test performed on the day of intervention\n* MSKCC patients\n\nExclusion Criteria:\n\n* Breast-feeding\n* History of renal functional disorders (chronic kidney disease with eGFR\\\u003C30)\n* Refusal or inability to tolerate the scanning procedure (e.g., due to claustrophobia)","18 Years",{"count":57,"type":20},30,"INTERVENTIONAL",[60],"EARLY_PHASE1","The purpose of this study is to determine the uptake of the imaging agent \\[68Ga\\]-pentixafor with PET\u002FCT scans in people with monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), and non-Hodgkin lymphoma (NHL), or you have histiocytic neoplasms (Langerhans cell histiocytosis (LCH), Erdheim-Chester disease (ECD) and\u002For Rosai-Dorfman disease (RDD).",[63,64,65,26,66],"Non-Hodgkin Lymphoma","Multiple Myeloma","Histiocytic Neoplasms","Rosai-Dorfman Disease",[68,69,70,71,72,73,74,75,76],"[68Ga]-Pentixafor","PET\u002FCT scan","In-human CXCR4 Imaging","21-356","Symptomatic multiple myeloma","pre-cursor myeloma","MGUS","SMM","Memorial Sloan Kettering Cancer Center","2026-02-04",{"date":79,"type":39},"2026-02-05",{"date":81,"type":39},"2021-10-01",{"date":83,"type":20},"2027-10",{"name":76,"class":46},{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":15,"minAge":55,"maxAge":92,"enrollmentInfo":93,"targetDuration":4,"studyType":58,"phases":95,"briefSummary":97,"conditions":98,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":47},"100607331","phase-2-efficacy-and-safety-of-the-rd-regimenlenalidomide-dexamethasone-for-rosai-dorfman-disease-100607331","NCT07187167","Efficacy and Safety of the RD Regimen(Lenalidomide, Dexamethasone) for Rosai-Dorfman Disease","Efficacy and Safety of the RD Regimen (Lenalidomide, Dexamethasone) in the Treatment of Rosai-Dorfman Disease: A Prospective, Multicenter, Single-Arm Study.","Inclusion Criteria:\n\n* Definitively diagnosed adult RDD patients;\n* Aged between 18 and 80 years;\n* Treatment-naive or refractory\u002Frelapsed;\n* ECOG performance status score ≤ 2;\n* Judged by clinicians as suitable for treatment with this protocol;\n* Patients or their families able to understand the study protocol and willing to participate in the study, providing written informed consent.\n\nExclusion Criteria:\n\n* Subjects who have undergone major surgery within 4 weeks prior to the first dose of the study;\n* Subjects who have received radiotherapy within 4 weeks prior to the first dose of the study;\n* Subjects with a history of myocardial infarction within the past year;\n* Patients with New York Heart Association (NYHA) Class 3 or 4 congestive heart failure, or a history of NYHA Class 3 or 4 congestive heart failure;\n* Pregnant or lactating women;\n* Patients who cannot strictly practice contraception after participating in the study;\n* Abnormal liver and kidney function: creatinine level ≥176.8 μmol\u002FL (2 mg\u002FdL), transaminase and bilirubin levels more than 2 times the upper limit of normal\n* Abnormal blood counts: absolute neutrophil count less than 1×10\\^9\u002FL, platelet count less than 50×10\\^9\u002FL;\n* Patients or their families who cannot understand the conditions and objectives of the study;\n* Any other situation where the investigator considers the patient unsuitable to participate in this trial.","80 Years",{"count":94,"type":20},40,[96],"PHASE2","In patients with Rosai-Dorfman disease (RDD), a treatment regimen of lenalidomide combined with dexamethasone is planned to be used.",[66],"2025-09-16",{"date":101,"type":39},"2025-09-22",{"date":103,"type":39},"2025-04-12",{"date":105,"type":20},"2027-04-12",{"name":107,"class":46},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":114,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":116,"targetDuration":4,"studyType":58,"phases":118,"briefSummary":119,"conditions":120,"keywords":126,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":138},"100368581","phase-2-cobimetinib-in-refractory-langerhans-cell-histiocytosis-lch-and-other-histiocytic-disorders-100368581","NCT04079179","Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders","A Phase 2 Study to Assess the Safety and Efficacy of Cobimetinib in Refractory Langerhans Cell Histiocytosis, LCH-Associated Neurodegenerative Disease, and Other Histiocytic Disorders.","NACHO-COBI","INCLUSION CRITERIA:\n\nAge at study entry\n\n* For Group 1: Participant must be at least 6 months of age and less than 21 years of age at the time of enrollment\n* For Group 2: Participant may be at least 6 months of age at the time of enrollment\n* For Group 3: Participant must be at least 6 months of age and less than 21 years of age at the time of enrollment\n* For Group 4: Participant must be 21 years of age or older at the time of enrollment\n* Participant must be able to take an enteral dose and formulation of medication. Study medication is only available as an oral suspension or tablet which may be taken by mouth or other enteral route such as nasogastric or gastric tube.\n* Biopsy proven LCH -AND\n* Failure of at least front-line therapy for LCH with evaluable disease. -OR\n* Diagnosis of LCH-associated neurodegenerative disease with radiologic or clinical progression within the past 3 months. -OR\n* Biopsy proven JXG, ECD, RDD, histiocytic sarcoma, or other histiocytic lesion (newly diagnosed or relapsed\u002Frefractory disease) with evaluable active disease.\n\nPerformance Level:\n\n-Karnofsky ≥ 50% for patients \\> 16 years of age and Lansky ≥ 50% for patients ≤ 16 years of age.\n\nAdequate Hematologic Function Defined as:\n\n* ANC ≥ 0.75 x 10\\^9\u002FL (unsupported\u002Fwithout growth factor stimulant)\n* Platelet count ≥ 75 x 10\\^9\u002FL (unsupported\u002Fwithout transfusion within the past 7 days).\n* Patients with marrow disease must have platelet count of \\>\u002F= 75 x 10\\^9\u002FL (transfusion support allowed) and must not be refractory to platelet transfusions.\n* Hemoglobin ≥ 8 g\u002FdL (unsupported\u002Fwithout transfusion within the past 7 days)\n* Patients with marrow disease must have hemoglobin ≥ 8 g\u002FdL (transfusion support allowed).\n\nAdequate Renal Function Defined as:\n\n\\- Calculated creatinine clearance (or radioisotope GFR) ≥ 70 mL\u002Fmin\u002F1.73m\\^2 or serum creatinine based on age\u002Fgender as follows:\n\nMaximum Serum Creatinine (mg\u002FdL) Age 2 to \\\u003C 6 years: Male 0.8 mg\u002FdL, Female 0.8; 6 to \\\u003C 10 years: Male 1 mg\u002FdL,Female 1; 10 to \\\u003C 13 years: Male 1.2 mg\u002FdL; Female 1.2; 13 to \\\u003C 16 years: Male 1.5 mg\u002FdL ; Female 1.4; ≥ 16 years: Male 1.7 mg\u002FdL; Female 1.4;\n\nAdequate Liver Function Defined as:\n\n* Bilirubin (sum of conjugated + unconjugated) ≤ 1.5 x upper limit of normal (ULN) for age\n* AST and ALT ≤ 3x ULN (≤ 5 x ULN for participants with liver involvement)\n* Serum albumin ≥ 2 g\u002FdL.\n\nFor patients with liver disease caused by histiocytic disorder:\n\n• Patients may be enrolled with abnormal bilirubin, AST, ALT and albumin with documentation of histiocytic liver disease.\n\nAdequate Cardiac Function Defined as:\n\n\\- Fractional shortening (FS) of ≥ 30% or ejection fraction of ≥ 50% by echocardiogram at baseline, as determined by echocardiography or multigated acquisition scan (MUGA) within 28 days prior to enrollment. Depending on institutional standard, either FS or LVEF is adequate for enrollment if only one value is measured; if both values are measured, then both values must meet criteria above\n\nPregnancy\u002FBirth Control\n\n* Female patients of childbearing potential require a negative urine or serum pregnancy test for eligibility and again at database registration, if more than 2 weeks has elapsed.\n* Female patients of childbearing potential must agree to follow the contraceptive requirements using two forms of effective contraceptive methods for the duration of the study treatment. Male patients with sexual partners who are pregnant or who could become pregnant (i.e., women of child-bearing potential) must agree to use two forms of effective methods of contraception (one of which must be a barrier method) during the treatment period and for at least 3 months after the last dose of the study drug to avoid pregnancy and\u002For potential adverse effects on a developing embryo. Agreement to true abstinence (not periodic abstinence or withdrawal method) is an acceptable method of birth control.\n\nEXCLUSION CRITERIA:\n\n\\- Prior and Concomitant Use of Drugs with CYP3A4 inducing\u002Finhibiting activity: Patient taking strong inducers or inhibitors of CYP3A4 within 14 days prior to study enrollment, including but not limited to the following: erythromycin, clarithromycin, ketoconazole, azithromycin, itraconazole, grapefruit juice or St. John's wort.\n\n* Prior Therapy Restrictions Completion of previous chemotherapy, immunotherapy, radiotherapy, or targeted therapy for LCH (or other histiocytic disorder) at least 28 days (except where specified below) prior to study enrollment, with resolution of all associated toxicity to ≤ Grade 1 prior to study enrollment (exception for alopecia and ototoxicity which do not need to be resolved ≤ Grade 1). Patients must have fully recovered from the acute toxic effects of all prior anti-cancer therapy and must meet the following minimum duration from prior anti-cancer directed therapy prior to enrollment. If after the required timeframe, the laboratory eligibility criteria are met, the patient is considered to have recovered adequately. See below for specific consideration of prednisone and corticosteroids prior to enrollment.\n\n  * Radiation therapy within the 14 days prior to enrollment.\n  * Any prior treatment with Cobimetinib.\n  * Treatment with a long-acting hematopoietic growth factor within 14 days prior to initiation of study drug or a short-acting hematopoietic growth factor within 7 days prior to enrollment.\n  * Treatment with hormonal therapy (except hormone replacement therapy or oral contraceptives), immunotherapy, biologic therapy, investigational therapy, or herbal cancer therapy within 28 days or \\\u003C 5 half-lives, whichever is longer, prior to study enrollment.\n  * Treatment with high-dose chemotherapy and stem-cell rescue (autologous stem cell transplant) or allogeneic stem cell transplant within 90 days prior to enrollment. Anti-GVHD agents post-transplant: Patients who are receiving cyclosporine, tacrolimus or other agents to prevent graft-versus-host disease post bone marrow transplant are not eligible for this trial.\n  * For patients with brain tumors (intracranial masses), use of anticoagulants within 7 days prior to enrollment.\n  * Corticosteroid therapy less than or equal to 0.5 mg\u002Fkg\u002Fday averaged during the 28 days prior to study enrollment is permissible. Patients receiving corticosteroids must be on a stable or decreasing dose for 14 days prior to enrollment and discontinue once study treatment has started.\n  * Patient has received treatment with investigational therapy within 4 weeks prior to initiation of study drug.\n  * Patients taking anticoagulants or have a pre-existing bleeding disorder unrelated to histiocytic disease.\n* Exclusions for other illness\n\n  * Other active malignancy or history of secondary malignancy.\n  * Refractory nausea and vomiting, malabsorption, external biliary shunt\n  * Infection: Patients who have a known active infection (excluding documented fungal infection of the nail beds) within 28 days prior to enrollment that has not completely resolved.\n  * Major surgical procedure or significant traumatic injury within 28 days prior to enrollment, or anticipation of need for major surgical procedure during the course of the study. Placement of a vascular access device or minor surgery is permitted within fourteen (14) days prior to study enrollment (provided that the wound has healed).\n  * History of significant bowel resection that would preclude adequate absorption or other significant malabsorptive disease.\n  * History of pneumonitis.\n  * Ophthalmologic considerations: Patients with known significant ophthalmologic conditions or known risk factors for retinal vein occlusion are not eligible. Specifically, patients with a history of retinal vein occlusion (RVO), retinal detachment, retinal pathology on ophthalmologic exam, retinopathy of prematurity, central serous chorioretinopathy (CSSCR), neovascular retinopathy, intraocular pressure \\> 21 mmHg, and predisposing factors to RVO (e.g., uncontrolled hypertension, diabetes, or hyperlipidemia, coagulopathy) will be excluded. Patients with longstanding and stable ophthalmologic findings secondary to existing conditions are eligible with appropriate written documentation and approval from Study Chair.\n  * History of solid organ transplantation: Patients who have received a prior solid organ transplantation are not eligible.\n  * Any other disease, metabolic or psychological dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that in the opinion of the investigator contraindicates use of an investigational drug or places the patient at unacceptable risk from treatment complications.\n* History of clinically significant cardiac dysfunction, including the following:\n\n  * Clinically significant cardiac arrhythmias including brady-arrhythmias and\u002For patients who require anti-arrhythmic therapy (with the exception of beta blockers or digoxin). Patients with controlled atrial fibrillation are not excluded.\n  * Unstable arrhythmia\n  * Unstable angina, or new-onset angina within 3 months prior to initiation of study treatment\n  * Symptomatic congestive heart failure, defined as New York Heart Association Class II or higher\n  * Myocardial infarction within 3 months prior to initiation of study treatment\n* Known chronic human immunodeficiency virus (HIV).\n* History of Grade ≥ 2 CNS hemorrhage or history of any CNS hemorrhage within 28 days of enrollment.\n* Female patients who are pregnant or lactating. Pregnant or lactating women will not be entered on this study because there is no available information regarding human fetal or teratogenic toxicities.",{"count":117,"type":20},90,[96],"This is a research study of a drug called cobimetinib in children and adults diagnosed with Langerhans cell histiocytosis (LCH), and other histiocytic disorders that has returned or does not respond to treatment. Cobimetinib blocks activation of a protein called Mitogen-activated protein kinase (MEK) that is part of incorrect growth signals in histiocytosis cells. Four different groups of patients will be enrolled.",[121,122,26,27,123,124,125],"Langerhan's Cell Histiocytosis","Juvenile Xanthogranuloma","Neuro-Degenerative Disease","Histiocytic Sarcoma","Histiocytic Disorders, Malignant",[127,128],"Cobimetinib","Langerhans Cell Histiocytosis (LCH)","2025-09-12",{"date":131,"type":39},"2025-09-18",{"date":133,"type":39},"2021-04-19",{"date":135,"type":20},"2029-12",{"name":137,"class":46},"Carl Allen",12]